EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial

C von Arx, G Della Vittoria Scarpati, L Cannella, O Clemente, A L Marretta, A Bracigliano, F Picozzi, D Iervolino, V Granata, R Modica, A Bianco, C Mocerino und 6 weitere

ESMO Open · 2024

DOI: 10.1016/j.esmoop.2024.103003 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift ESMO Open, 2024. Verfasst von C von Arx und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples. Ele…. Hauptthemen laut MEDLINE: Temozolomide, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministero della Salute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There is no consensus on the second-line treatment of patients with progressive high-grade neuroendocrine neoplasms (NENs G3) and large-cell lung neuroendocrine carcinoma. These patients generally have poor performance status and low tolerance to combination therapy. In this trial, we aim to evaluate the efficacy and safety of temozolomide given every other week in patients with advanced platinum-pretreated NENs G3. PATIENTS AND METHODS: This trial is an open-label, non-randomized, phase II trial. Patients with platinum-pretreated metastatic neuroendocrine carcinoma were treated with 75 mg/m2/day of temozolomide for 7 days, followed by 7 days of no treatment (regimen one week on/one week off). The primary endpoint was the overall response rate. Secondary endpoints included progression-free survival (PFS), overall survival (OS), safety and tolerability. This study is registered with ClinicalTrials.gov, NCT04122911. RESULTS: From 2017 to 2020, 38 patients were enrolled. Among the patients with determined Ki67, 12 out of 36 (33.3%) had a Ki67 index

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideCarcinoma, NeuroendocrineHumansMaleFemaleMiddle AgedAgedAdultAntineoplastic Agents, AlkylatingDrug Administration ScheduleLung NeoplasmsProgression-Free Survival

Stichwörter der Autor:innen

NECmetronomicneuroendocrine tumorsperformance statustemozolomide

Substanzen

TemozolomideAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples. Electronic address: claudia.vonarx@istitutotumori.na.it.
  • Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori - I.R.C.C.S. Fondazione "G.Pascale", Naples.
  • Medical Oncology Unit, Ospedale Ave Gratia Plena, San Felice a Cancello, Caserta.
  • Nuclear Medicine, Istituto Nazionale Tumori - I.R.C.C.S. Fondazione "G. Pascale", Naples.
  • ISS Clinica di Domenico Iervolino, Palma Campania, Naples.
  • Radiology Unit, Istituto Nazionale Tumori - I.R.C.C.S. Fondazione "G. Pascale", Naples.

Förderung

  • Ministero della Salute

Zitieren

APA

von Arx, C., Della Vittoria Scarpati, G., Cannella, L., Clemente, O., Marretta, A. L., Bracigliano, A., Picozzi, F., Iervolino, D., Granata, V., Modica, R., Bianco, A., Mocerino, C., Di Mauro, A., Pizzolorusso, A., Di Sarno, A., Ottaiano, A., Tafuto, S., & ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET (2024). A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial. ESMO Open. https://doi.org/10.1016/j.esmoop.2024.103003

Vancouver

von Arx C, Della Vittoria Scarpati G, Cannella L, Clemente O, Marretta AL, Bracigliano A, et al. A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial. ESMO Open. 2024. doi:10.1016/j.esmoop.2024.103003

BibTeX
@article{vonArx2024,
  author = {von Arx, C and Della Vittoria Scarpati, G and Cannella, L and Clemente, O and Marretta, A L and Bracigliano, A and Picozzi, F and Iervolino, D and Granata, V and Modica, R and Bianco, A and Mocerino, C and Di Mauro, A and Pizzolorusso, A and Di Sarno, A and Ottaiano, A and Tafuto, S and ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET, ENETs Center of Excellence in Naples, Italy and with the endorsement of the Italian Association for Neuroendocrine Tumor IT.A.NET},
  title = {A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial},
  journal = {ESMO Open},
  year = {2024},
  doi = {10.1016/j.esmoop.2024.103003}
}
Kostenlos starten →